In addition, knockdown of TPD52L2 can inhibit the proliferation of HCC cells in vitro, suggesting that TPD52L2 may be a potential target for the diagnosis and treatment of HCC [36]. Here, TPD52L2 is linked to hepatocellular carcinoma.